“A recent study showed that the first-line empagliflozin, taken once per day for three months, led to a significant reduction in weight, body mass index (BMI), and waist circumference in patients with prediabetes and diabetes.”

A study conducted in Iran evaluated the effects of empagliflozin as a first-line treatment in patients with prediabetes and diabetes. It was observed that When administered once per day over three months, empagliflozin significantly reduced body weight, body mass index (BMI), and waist circumference.

 The study included 43 participants and reported significant decreases in body weight, BMI, waist circumference, fasting plasma glucose (FPG), and A1c levels after 12 weeks of treatment.

Men experienced greater weight loss than women, although BMI and waist circumference changes were similar between genders. Patients with a glomerular filtration rate (GFR) above 90 demonstrated greater weight reduction compared to those with a GFR below 90, but the difference was not statistically significant. Weight and BMI continued to decline steadily throughout the three months without reaching a plateau, whereas waist circumference changes plateaued after the first month of treatment.

These findings are consistent with prior research highlighting the weight-loss benefits of empagliflozin.

(Source:https://www.medscape.com/viewarticle/empagliflozin-aids-weight-loss-prediabetes-and-diabetes-2025a10000yd)